Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals International, plc (KNSA) filed a Form 144 notifying a proposed sale of 49,407 Class A ordinary shares on 08/12/2025, with an aggregate market value of $1,600,641.00. The shares represent part of the issuer's 43,472,928 outstanding shares and are to be sold on NASDAQ through Charles Schwab & Co., Inc.. The securities were acquired the same day via an employee stock option exercise and settled by a broker payment for cashless exercise. The filer reported "Nothing to Report" for sales in the past three months and included the standard representation that the seller is not aware of undisclosed material adverse information.
John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals (KNSA), exercised 29,325 share options at an exercise price of $3.80 and sold 29,325 Class A Ordinary Shares at a weighted average price of $32.55 under a Rule 10b5-1 trading plan. The filing states the option is fully vested and exercisable and reports post-transaction beneficial ownership figures of 86,728 and 57,403 Class A shares, plus 36,542 derivative securities. The sale was executed through a broker-dealer in multiple trades and the filer offers to provide trade-level price details on request.
Report: Form 4 filed for Ragosa Mark (address: 23 Old Bond Street, London) reporting transactions in Kiniksa Pharmaceuticals International, plc (KNSA). The reporting person is identified as a Director and Chief Financial Officer. Earliest transaction date: 08/04/2025. Form signed by Madelyn Zeylikman, Attorney-in-Fact, dated 08/06/2025.
Transactions: Table I shows two Class A Ordinary Share transactions on 08/04/2025 involving 18,889 shares at prices of $22.89 and $32.89, with reported post-transaction beneficial ownerships of 45,898 and 27,009. Table II reports a Share Option with exercise/conversion price $22.89 covering 18,889 underlying Class A shares, expiration 03/15/2031, and 2,036 derivative securities reported beneficially owned following the transaction. The filing states the transactions were effected pursuant to a 10b5-1 plan executed Sept 3, 2024 and discloses the option vesting schedule (vesting commencement 03/16/2021; 25% on first anniversary; monthly vesting over 36 months).